Registry of liver cancer patients in China

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to create a standardized clinical information database for patients diagnosed with various forms of liver cancer, including hepatocellular carcinoma and its variants. Led by the Department of Hepatobiliary Surgery at the First Affiliated Hospital of the University of Science and Technology of China, the study involves collaboration with multiple hospitals across the country. The database will facilitate high-quality real-world clinical studies and enhance clinical research in liver cancer management.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age ≥ 18 years, no gender limit
* Patients without surgery are initially diagnosed with hepatocellular carcinoma, intrahepatic cholangiocarcinoma, mixed hepatocellular carcinoma-cholangiocarcinoma, or metastatic hepatocellular carcinoma based on the results of imaging and laboratory tests, or patients with surgery are diagnosed with hepatocellular carcinoma, intrahepatic cholangiocarcinoma, mixed hepatocellular carcinoma-cholangiocarcinoma, or metastatic hepatocellular carcinoma based on the results of pathologic tests
* Signed informed consent, good compliance, willingness to accept follow-up and provide blood and postoperative pathology residual samples

Exclusion Criteria:

* Combination of severe central nervous system disease, respiratory disease, autoimmune disease, chronic renal insufficiency, long-term use of immunosuppressive drugs, combination of severe uncontrolled infections
* Concurrent active cardiovascular disease, cerebrovascular accident within 6 months, myocardial infarction, unstable angina pectoris, or congestive heart failure of class II or greater according to the New York Heart Association criteria, severe arrhythmia requiring medication
* Pregnant or breastfeeding women
* Participation in other therapeutic clinical trials during the course of the patient's illness in which the treatment cannot be specified or information about the treatment cannot be collected

Where it's running

• Anqing First People's Hospital
  Anqing, Anhui, China Recruiting
• Anqing Municipal Hospital
  Anqing, Anhui, China Recruiting
• Bengbu First People's Hospital
  Bengbu, Anhui, China Recruiting
• The First Affiliated Hospital of Bengbu Medical University
  Bengbu, Anhui, China Recruiting
• The Second Affiliated Hospital of Bengbu Medical College
  Bengbu, Anhui, China Recruiting
• The People's Hospital of Bozhou
  Bozhou, Anhui, China Recruiting

Study contacts

• Study coordinator: Ji-Zhou Wang, MD PhD
• Email: wangjoe@ustc.edu.cn
• Phone: +86 13836135864

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Integrated genomic and clinical database for cancer biomarker discovery

  Researchers are building a combined genomic and clinical database at Samsung Medical Center to test biomarkers for cancer diagnosis, treatment choice, and predicting how well treatments work.

  Recruiting Samsung Medical Center · Seoul, Gang-Nam · NCT07911267

• BGB-B2033 vs Sorafenib or Lenvatinib for advanced liver cancer

  This study tests whether the investigational drug BGB-B2033 can help people with advanced hepatocellular carcinoma when given after prior PD-1/PD-L1 therapy, compared with the standard medicines sorafenib or lenvatinib.

  Recruiting at 2 sites Phase 3 BeOne Medicines · South Brisbane, Queensland and 1 other locations · NCT07836530

• Protoacoustic Imaging to See Radiation Delivery in Proton Therapy

  This study tests radioacoustic imaging with ultrasound to help doctors see where proton therapy is delivering radiation for liver and prostate cancer patients.

  Recruiting University of Oklahoma · Oklahoma City, Oklahoma · NCT07832617

• YMN-136 vaccine for advanced liver, biliary tract, and pancreatic cancers

  A first-in-human dose-escalation study tests whether the YMN-136 vaccine is safe and tolerable for adults with unresectable advanced liver, biliary tract, or pancreatic cancers who have progressed on standard therapies or cannot receive them.

  Recruiting Phase 1 West China Hospital · Chengdu, Sichuan · NCT07763301

• DRAGON: International registry for patients who had combined portal and hepatic vein embolization before liver surgery

  This registry collects data on patients who had PVE/HVE before liver resection to see if it helps liver regeneration and what factors relate to outcomes.

  Recruiting at 30 sites Maastricht University Medical Center · Chicago, Illinois and 30 other locations · NCT07717437

• Precision navigation to boost cancer screening participation in high-risk communities

  This study tests whether a personalized navigation program helps adults aged 45–74 in Chinese communities who are at high risk for several cancers to complete recommended free cancer screenings.

  Recruiting at 3 sites Hunan Cancer Hospital · Huaihua, Hunan and 2 other locations · NCT07676383

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.